BEONE MEDICINES Reports BRUKINSA Captures Over Half of New CLL/SLL Patient Share

Deep News08-07 21:53

BEONE MEDICINES disclosed during a recent investor briefing that, while different data sources may show slight variations in measuring new patient market share in the United States, BRUKINSA has already secured more than half of new CLL/SLL patients, reaching a significant level.

The company noted that the conversion of new patient share into revenue is a gradual process. Newly diagnosed patients accumulate over time, becoming part of the existing patient pool, and contribute increasing revenue as their treatment duration extends. The average duration of therapy (DoT) currently stands at approximately 42 months, which is expected to continue rising as patients accumulate and data matures. As a result, BRUKINSA is still far from reaching its peak sales potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment